May 14, 2026 8:05am EDT Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026 7:00am EDT Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Apr 28, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Mar 31, 2026 8:05am EDT Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Mar 03, 2026 4:01pm EST Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Feb 24, 2026 8:05am EST Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
